Royalty Pharma Q2 GAAP net income attributable to company falls 44% to $18 million; non-GAAP adjusted EBITDA rises 16% to $736 million - RPRX News | Rallies
Royalty Pharma Q2 GAAP net income attributable to company falls 44% to $18 million; non-GAAP adjusted EBITDA rises 16% to $736 million R RPRX • 2026-08-05 Second-quarter results
Royalty Pharma posted second-quarter results with net cash from operating activities more than doubling to $728 million .
Portfolio Receipts rose 6% to $773 million , while Royalty Receipts climbed 14% to $768 million .
Net income attributable to shareholders fell to $18 million , while GAAP operating income dropped 37% to $133 million .
Non-GAAP adjusted EBITDA increased 16% to $736 million ; capital deployment totaled $349 million .
The company raised 2026 Portfolio Receipts guidance to $3.4 billion-$3.5 billion and acquired a cliramitug royalty for up to $425 million .
KHC
•
2026-08-05
RPRX•
